Infectious Disease Deal Benchmarks
Benchmark deal terms across vaccines, HIV, hepatitis B functional cure programs, RSV prevention, and next-generation antibiotics. Post-pandemic platforms continue driving partnership activity. Benchmarks derived from 390 verified transactions.
390
Total Deals
$213M
Avg Upfront
7
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
205
license
73
acquisition
84
collaboration
18
option
8
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Ferring Pharmaceuticals → RedHill Biopharma Rebyota (global) and Clenpiq (US) | license | $12M | — | Sep 2026 |
PolyPid Ltd. → Azurity Pharmaceuticals D-PLEX100 | license | $15M | $320M | Jul 2026 |
Matinas BioPharma Holdings, Inc. → Azurity Pharmaceuticals, Inc. MAT2203 | acquisition | $4M | $22M | Jul 2026 |
Memo Therapeutics AG → Ipsen potravitug | acquisition | $224M | $784M | Jul 2026 |
Sanofi → Gujarat Themis Biosyn 13 anti-tuberculosis and anti-infective brands portfolio | acquisition | $175M | $175M | Apr 2026 |
Aligos Therapeutics → Amoytop Biotech pevifoscorvir sodium | collaboration | $25M | $445M | Apr 2026 |
Aligos Therapeutics, Inc. → Xiamen Amoytop Biotech Co., Ltd. pevifoscorvir sodium | license | $25M | $445M | Apr 2026 |
Novavax → Pfizer Matrix-M | license | $30M | $530M | Apr 2026 |
GSK → Arrowhead JNJ-3989 | license | $1.0B | — | Apr 2026 |
Bluejay Therapeutics → Mirum Pharmaceuticals phase 3 hepatitis B/D drug | acquisition | $620M | $820M | Mar 2026 |
Benchmark Your Infectious Disease Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 390 verified infectious disease transactions.
Infectious Disease Deal Benchmarking FAQ
How did COVID reshape infectious disease deal structures?
The pandemic permanently changed infectious disease deal-making by validating mRNA and viral vector platforms. Post-COVID deals increasingly feature platform licensing (not just single products), with licensees securing access to technology for multiple pathogens. Upfronts for platform deals range $100M-$500M+, significantly above pre-pandemic levels.
What are current HBV functional cure deal terms?
Hepatitis B functional cure programs are one of the most active segments, with multiple mechanisms (siRNA, ASO, capsid inhibitors, immunotherapy) being licensed. Combination approach deals are common, with upfronts of $50M-$200M and total deal values exceeding $1B for programs targeting the estimated 300M chronic HBV patients worldwide.
How do antibiotic deal structures address the commercial challenge?
Antibiotic deals are uniquely structured to address the "broken economics" of antimicrobials. Pull incentives (subscription models, guaranteed revenue floors) are increasingly incorporated into deal terms. Upfronts are typically lower ($10M-$50M) but include novel milestone structures tied to regulatory designations (QIDP, GAIN Act) rather than traditional sales thresholds.